Nomura Holdings
CYTK icon

Nomura Holdings’s Cytokinetics CYTK Stock Holding History

Nomura Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,000
Closed -$1.98M – 1858
2026
Q1 		$1.98M Sell
30,000
-77,200
-72% -$4.91M 0.01% 932
2025
Q4 		$6.81M Buy
107,200
+3,200
+3% +$199K 0.01% 678
2025
Q3 		$5.72M Sell
104,000
-26,200
-20% -$1.08M 0.01% 715
2025
Q2 		$4.3M Buy
130,200
+101,500
+354% +$3.53M 0.01% 612
2025
Q1 		$1.15M Sell
28,700
-105,000
-79% -$4.83M ﹤0.01% 1232
2024
Q4 		$6.29M Buy
133,700
+8,700
+7% +$452K 0.01% 682
2024
Q3 		$6.6M Hold
125,000
– – 0.02% 563
2024
Q2 		$6.77M Sell
125,000
-400,000
-76% -$24.1M 0.01% 583
2024
Q1 		$36.8M Buy
525,000
+492,600
+1,520% +$38.1M 0.09% 164
2023
Q4 		$2.71M Buy
+32,400
New +$1.17M 0.01% 874

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's CYTK Position: Q2 2026 in Review

Nomura Holdings increased its Cytokinetics (CYTK) stake by 723% in Q2 2026, buying an estimated $2.14M and bringing the position to 34,000 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #972.

Nomura Holdings first reported a position in CYTK in Q1 2014 and has held it in 13 quarters since. The position peaked at $7.76M in Q3 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Nomura Holdings held 34,000 shares of Cytokinetics worth $2.9M as of Q2 2026.
  • Nomura Holdings bought 29,870 Cytokinetics shares in Q2 2026, an estimated $2.14M.
  • Cytokinetics made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #972 holding.
  • Nomura Holdings first reported a position in Cytokinetics in Q1 2014 and has held it in 13 quarters since.
  • Nomura Holdings's Cytokinetics position peaked at $7.76M in Q3 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.